AngioSoma has a robust product pipeline, with patents, provisional patents, expired patents
with corporate intellectual property / knowledge, registered trademarks, and many more to come.
Here are the most important current corporate assets that contribute to our shareholder value.
Liprostin™ is a treatment for PAD that has completed FDA Phase I and three Phase II clinical trials. We are in discussions with contract research organizations (“CRO”) for completion of our U.S. Food and Drug Administration (“FDA”) protocol for Phase III and submission of our new drug application for marketing in the US and its territories.
TRANSDERMAL PGE-1 PATCH
The Transdermal PGE-1 Patch for the delivery of PGE-1 and / or Liprostin™ through the skin for the treatment of cardiovascular diseases is part of a group of 2 Provisional US Patents and 2 Non-Provisional US Patents filed in September 2016 by AngioSoma, Inc.
OMNICATH I & OMNICATH II
The OmniCath I is an atherectomy catheter that helps plaque removal by drilling, pulverizing and shaving it. The OmniCath I is protected by US Patent 5,728,129, and AngioSoma, Inc. is filing new patents currently which will, in conjunction with the original base patent, create the OmniCath™ II.
Our products have previously generated over ten million dollars ($10,000,000) in sales, through various sales outlets including GNC.
like Business Wire, but it provides the same news here in an expanded format with links to all of the initial released
locations and expanded images. This conforms to Regulation FD disclosure requirements.
AngioSoma, Inc. (OTC: SOAN) Announces Completion of Products for Market Business Wire HOUSTON — February 5, 2018 We are pleased…